Cargando…

Correspondence Regarding “Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors”

Detalles Bibliográficos
Autores principales:	Takada, Kazuki, Takamori, Shinkichi, Miura, Naoko, Shikada, Yasunori, Shimokawa, Mototsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629511/ https://www.ncbi.nlm.nih.gov/pubmed/34870248 http://dx.doi.org/10.1016/j.jtocrr.2021.100238

Ejemplares similares

Re: COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a worldwide survey (The INTENSIVE study)
por: Takada, Kazuki, et al.
Publicado: (2021)

Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials
por: Takada, Kazuki, et al.
Publicado: (2022)

Correspondence Regarding “Sleeve Lobectomy After Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for Squamous Cell Lung Cancer: A Multicenter, Retrospective Study”
por: Takada, Kazuki, et al.
Publicado: (2023)

Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors
por: Ballman, Madison, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
por: Dickerman, Barbra A., et al.
Publicado: (2021)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
por: Thompson, Mark G., et al.
Publicado: (2021)

BNT162b2, mRNA-1273, et EMA : une procédure qui roule
por: Dalmat, Yann-Mickael
Publicado: (2021)

The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273
por: Markewitz, Robert, et al.
Publicado: (2022)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
por: Goddard, Kristin, et al.
Publicado: (2022)

Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non‐small‐cell lung cancer: Real‐world data from 86 173 patients
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Impact of Liver Metastasis on First-Line Immunotherapy in Stage IV Non-Small Cell Lung Cancer
por: Komiya, Takefumi, et al.
Publicado: (2023)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022)

BNT162b2, mRNA-1273 : des vaccins mis en examen à l’EMA
por: Manus, Jean-Marie
Publicado: (2021)

Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
por: Mavrovouniotis, Ilias, et al.
Publicado: (2023)

Assessment of Intraoperative Microbiological Culture in Patients with Empyema: Comparison with Preoperative Microbiological Culture
por: Akamine, Takaki, et al.
Publicado: (2021)

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients
por: Bagacean, Cristina, et al.
Publicado: (2021)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
por: Hammer, Helly, et al.
Publicado: (2022)

Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
por: Haq, Hannah N., et al.
Publicado: (2022)

POS-975 SEROLOGIC RESPONSE TO THE mRNA-1273 and BNT162b2 COVID-19 VACCINES IN DIALYSIS PATIENTS
por: Yau, K., et al.
Publicado: (2022)

B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
por: Markewitz, Robert, et al.
Publicado: (2022)

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
por: Puranik, Arjun, et al.
Publicado: (2022)

Myocarditis after BNT162b2 and mRNA-1273 COVID-19 vaccination: A report of 7 cases
por: Ahmed, Sirwan Khalid
Publicado: (2022)

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
por: Naveed, Zaeema, et al.
Publicado: (2022)

Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients
por: Haller, Maria C., et al.
Publicado: (2022)

Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2022)

mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations
por: Carreño, Juan Manuel, et al.
Publicado: (2022)

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
por: Matsubara, Taichi, et al.
Publicado: (2020)

Distinct glomerular disease association after vaccination with BNT162b2 and mRNA-1273: a VigiBase analysis
por: Kronbichler, Andreas, et al.
Publicado: (2022)

Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles
por: Kaplonek, Paulina, et al.
Publicado: (2021)

Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
por: Naranbhai, Vivek, et al.
Publicado: (2021)

Antibody Response to Vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms
por: Rotterdam, Jil, et al.
Publicado: (2021)

Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
por: Islam, Nazmul, et al.
Publicado: (2022)

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
por: Kaplonek, Paulina, et al.
Publicado: (2022)

Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
por: Korosec, Chapin S., et al.
Publicado: (2022)

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
por: Montoya, José G., et al.
Publicado: (2021)

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients
por: Broseta, José Jesús, et al.
Publicado: (2021)

Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial
por: Janssen, Cécile, et al.
Publicado: (2022)

Protective antibody response to mRNA-1273 and BNT162b2 vaccines in patients on maintenance haemodialysis: a prospective cohort study
por: Dimitrov, Yves, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vrlfs5ca126cik46895a1h605e